SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In a recent meta-analysis that included 12 phase 2 RCTs with aggregate data on 850 middle-aged overweight or obese individuals with NAFLD (most of whom had coexisting T2D), Mantovani et al. reported that, compared to a placebo or reference therapy, treatment with SGLT-2 inhibitors for 24 weeks (mostly empagliflozin and dapagliflozin) was associated with significant reductions in serum liver enzyme levels as well as in the absolute percentage of liver fat content, as assessed with magnetic-resonance-based techniques (pooled weighted mean difference: −2.05%, 95% CI −2.61 to −1.48%) [136].